소수성 상호작용 크로마토그래피 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the hydrophobic interaction chromatography market size is expected to grow from USD 479.69 million in 2025 to USD 513.41 million in 2026 and is forecast to reach USD 721.09 million by 2031 at 7.03% CAGR over 2026-2031.

This report is Segmented by Product (Columns {Axial Flow, Radial Flow} and Resins {Agarose-Based and More), Technology (Classical HIC, and More), Sample Type (Monoclonal Antibodies, Antibody-Drug Conjugates, and More), End User (Pharma & Biopharma Companies, and More), and Geography (North America, Europe, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Hydrophobic Interaction Chromatography Market Trends and Insights

Growing Demand for Monoclonal Antibodies

Rising antibody titers have moved average commercial bioreactor campaigns above 5 g/L, which intensifies downstream bottlenecks that only hydrophobic interaction chromatography market workflows currently address with proven robustness. Manufacturing economics reveal that purification at times consumes 80% of the total cost of goods, sharpening management focus on fewer, higher capacity HIC steps that retain product quality. Fujifilm's USD 1.2 billion North Carolina expansion alone adds 160,000 L dedicated to antibodies and immediately lifts regional demand for HIC resins and columns. Host-cell protein specifications trending below 100 ppm make the polishing power of HIC indispensable for late-stage process qualification. The knock-on effect is steady double-digit revenue visibility for hydrophobic interaction chromatography market suppliers through mid-term planning cycles.

Surge in Global Biopharma Manufacturing Capacity

Asia-Pacific governments are pouring incentives into GMP plants, and the region's stainless-steel volume is rising faster than anywhere else, opening a persistent gap for purification infrastructure.Samsung Biologics and Lotte Biologics together earmark more than USD 4.8 billion for large-scale facilities, each engineered around state-of-the-art downstream halls that feature sizable HIC suites. Harmonized standards under the Pharmaceutical Inspection Co-operation Scheme are eliminating specification ambiguity, so buyers are free to select higher-performance hydrophobic chromatography market equipment rather than the lowest-cost legacy gear. Local production of columns and resins, such as Cytiva's new plant in Incheon, reduces lead times and foreign-exchange exposure, prompting multinationals to re-balance sourcing toward the region. As a result, capacity increments translate directly to resin pull-through, strengthening the hydrophobic interaction chromatography industry revenue base.

Shortage of Skilled Downstream Processing Talent

Industry 4.0 initiatives mandate data-science competencies that remain scarce, driving wage inflation and project delays when firms roll out continuous HIC trains. Programming languages such as Python and R are now basic requirements for chromatography data handling, yet only a fraction of process engineers possess such skills, lengthening validation timelines. Labor costs outstrip raw-material spending by an order of magnitude at pilot scale, so unfilled roles directly dent operating margins and slow new hydrophobic interaction chromatography market installations. Vendor-hosted academies partially close gaps, but emerging-market buildouts still outpace talent development, which could temper near-term uptake. Until curricula evolve, the skills deficit will be an immediate drag on the hydrophobic interaction chromatography market momentum.

Other drivers and restraints analyzed in the detailed report include:

1. Advances in High-Throughput HIC Resins & Columns
2. Rising R&D Spending on Antibody-Drug Conjugates
3. Availability of Alternative Chromatography Modes

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Columns dominate with 40.62% 2025 revenue because end-users favor equipment that pairs well with validated automation scripts and meets agency filings without amendments. Large axial configurations still headline high-volume installations, though radial designs gain popularity where throughput pressure drop trade-offs tilt economics. End-users lean on robust pack integrity testing and proven cleaning protocols, choosing established column brands even when alternate devices advertise higher capacity, thus anchoring the hydrophobic interaction chromatography market around legacy footprints. Columns also benefit from a wide network of third-party skid integrators, simplifying procurement and validation across multi-plant networks. In turn, scale stability and familiar control interfaces lessen operator training burdens, a decisive factor amid acute workforce shortages. Though membrane modules nibble at small-lot processes, columns remain the default when batch sizes exceed 2,000 L because resin reuse amortizes capital outlays over longer campaigns. Resin internal diffusion constraints continue to set flowrate ceilings, but suppliers are now optimizing bead architecture to double volumetric productivity without altering system hydraulics. As regulatory bodies stay cautious about wholesale hardware swaps, columns will remain centre-stage in the hydrophobic interaction chromatography market even as adjacent formats proliferate.

Resins underpin the highest growth trajectory at 9.52% CAGR due to rapid adoption of mixed-mode ligands pursuing better selectivity at lower salt. Agarose matrices command premium share on biocompatibility, while polymeric beads claim ground where alkaline cleaning or high pressure demands apply. Manufacturers channel heavy investment into ligand chemistry that uses shorter synthesis paths, cutting lead times and reducing carbon intensity in keeping with ESG reporting duties. Purolite's USD 150 million Pennsylvania site for agarose resin greatly enlarges North America's local supply, trims geopolitical risk, and elevates service levels through regional warehousing. Buyers reward such resilience with multi-year dual-sourcing agreements that lock volume and price, stabilizing the hydrophobic interaction chromatography market size for consumables sourcing teams. As upstream densities keep trending higher, dynamic capacity becomes the procurement scorecard; hence resin innovation remains the decisive variable that shapes the total addressable hydrophobic interaction chromatography market.

With decades of process characterization data and copious regulatory precedents. Process transfer risk remains low, and that reliability convinces quality leadership teams to stay with familiar salt-gradient workflows. Validation documentation from older biologics portfolios doubles as a template for new products, which compresses development calendars and curbs consulting spend. The hydrophobic interaction chromatography market, therefore, leans on established ligands like phenyl and butyl, whose robustness is thoroughly understood under multi-cycle cleaning regimens. Switching costs extend beyond consumables, touching every line in electronic batch records, so finance teams often prefer incremental process bolstering instead of full re-engineering. Even within continuous designs, classical packed beds nest comfortably inside switching valve matrices, further protecting their installed base.

Hydrophobic-charge induction chromatography is the fastest climber because it marries hydrophobic and electrostatic interactions, letting developers elute sensitive payloads at near-neutral pH. Its growing dossier of regulatory filings for viral vector and ADC products elevates confidence among quality functions that guard against late-stage surprises. Protein scientists appreciate HCIC for resolving subtle glycoform differences without extreme salt or pH, which avoids product degradation and preserves potency. Vendors now supply predictive simulation tools that shorten resin screening to weeks, not months, expanding the hydrophobic interaction chromatography market use case in strained development timelines. As more biopharmas pivot toward highly modified antibody scaffolds, HCIC's differentiated selectivity secures repeating orders and paves the way for platform adoption.

Complete Report Scope:

• By Product
  • Columns
    • Axial flow columns
    • Radial flow columns
  • Resins
    • Agarose-based resins
    • Polymer-based resins
    • Silica-based resins
  • Buffers
    • Kosmotropic salts
    • Additives & modifiers
• By Technology
  • Classical HIC
  • Hydrophobic-Charge Induction Chromatography (HCIC)
  • Mixed-mode HIC resins
• By Sample Type
  • Monoclonal antibodies
  • Antibody-drug conjugates
  • Vaccines
  • Viral vectors & gene-therapy products
  • Other recombinant proteins
• By End-User
  • Pharma & Biopharma Companies
  • Contract Development & Manufacturing Orgs (CDMOs)
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commands 37.12% of 2025 revenue and holds a deep bench of innovators, contract manufacturers, and tool suppliers whose proximity shortens supply chains and speeds service response. The Food and Drug Administration endorses continuous manufacturing. It publishes guidance that clarifies expectations for in-line monitoring, thereby emboldening adopters of membrane-based continuous HIC in pilot and commercial settings. United States federal incentives, including recent tax credits for biologics infrastructure, lower effective capital cost, and underpin orders for high-throughput column skids. Canada pursues complementary investments in antibody facilities, while Mexico advances regional fill-finish hubs that create incremental resin demand. As these networks interlink, cross-border logistics keeps lead times short and deepens the hydrophobic interaction chromatography market footprint.

Europe remains a powerhouse driven by the European Medicines Agency's harmonized framework, which facilitates quick mutual recognition of new purification technologies. Germany's concentration of biotech clusters, coupled with carbon-reduction targets, pushes suppliers to design low-solvent HIC workflows suited for ISO 14064 reporting. The United Kingdom safeguards its post-Brexit life-sciences status by fast-tracking advanced therapy applications, many requiring viral vector purification where HIC plays a central role. Southern European states leverage EU recovery funds to modernize biologics plants, inserting automated HIC steps to meet export quality tiers. Environmental, social, and governance (ESG) rules also force manufacturers to adopt resins with lower chemical footprints, further shaping the regional hydrophobic interaction chromatography industry narrative.

Asia-Pacific delivers the fastest 10.85% CAGR as China, India, and South Korea race to secure biopharma self-sufficiency and capture contract manufacturing flows. Massive campus-style projects, typified by Samsung Biologics and Lotte Biologics, integrate upstream, downstream, and fill-finish units in a single site, locking in long-term resin and column demand. Governments extend tax holidays and accelerated depreciation to shorten payback periods, while local regulators endorse Pharmaceutical Inspection Co-operation Scheme alignment, smoothing export clearance. Japanese innovators inject process-development rigor and collaborate with global suppliers to pilot membrane HIC solutions, seeding technology spill-overs region-wide. Southeast Asian nations add smaller multiproduct plants, thereby broadening customer bases for hydrophobic interaction chromatography market suppliers that offer modular, quick-turnaround packages.

1. Bio-Rad Laboratories
2. Danaher
3. GE Healthcare Life Sciences
4. Sartorius
5. Thermo Fisher Scientific
6. Merck KGaA (MilliporeSigma)
7. Tosoh Bioscience LLC
8. Waters Corporation
9. Agilent Technologies
10. Shimadzu
11. YMC Co. Ltd.
12. Sepax Technologies Inc.
13. Repligen
14. KNAUER Wissenschaftliche Gerate GmbH
15. JNC
16. Bio-Works Technologies AB
17. Pall
18. Phenomenex Inc.
19. ChromaTan Corporation
20. Daicel Chiral Technologies

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Demand For Monoclonal Antibodies
  • 4.2.2 Surge In Global Biopharma Manufacturing Capacity
  • 4.2.3 Advances In High-Throughput HIC Resins & Columns
  • 4.2.4 Rising R&D Spending On Antibody-Drug Conjugates
  • 4.2.5 Continuous-Processing Adoption Needs HIC Membranes
  • 4.2.6 Regulatory Push For Low-Salt Purification Workflows
• 4.3 Market Restraints
  • 4.3.1 Shortage Of Skilled Downstream Processing Talent
  • 4.3.2 Availability Of Alternative Chromatography Modes
  • 4.3.3 High Cost Of Premium HIC Equipment & Consumables
  • 4.3.4 Shift Toward Single-Use Affinity Membranes Bypassing HIC
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
  • 4.6.1 Evolution of hydrophobic-charge induction chromatography
  • 4.6.2 Radial-flow & membrane-based HIC platforms
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product
  • 5.1.1 Columns
    • 5.1.1.1 Axial flow columns
    • 5.1.1.2 Radial flow columns
  • 5.1.2 Resins
    • 5.1.2.1 Agarose-based resins
    • 5.1.2.2 Polymer-based resins
    • 5.1.2.3 Silica-based resins
  • 5.1.3 Buffers
    • 5.1.3.1 Kosmotropic salts
    • 5.1.3.2 Additives & modifiers
• 5.2 By Technology
  • 5.2.1 Classical HIC
  • 5.2.2 Hydrophobic-Charge Induction Chromatography (HCIC)
  • 5.2.3 Mixed-mode HIC resins
• 5.3 By Sample Type
  • 5.3.1 Monoclonal antibodies
  • 5.3.2 Antibody-drug conjugates
  • 5.3.3 Vaccines
  • 5.3.4 Viral vectors & gene-therapy products
  • 5.3.5 Other recombinant proteins
• 5.4 By End-User
  • 5.4.1 Pharma & Biopharma Companies
  • 5.4.2 Contract Development & Manufacturing Orgs (CDMOs)
  • 5.4.3 Contract Research Organizations (CROs)
  • 5.4.4 Academic & Research Institutes
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 Bio-Rad Laboratories Inc.
  • 6.3.2 Danaher (Cytiva)
  • 6.3.3 GE Healthcare Life Sciences
  • 6.3.4 Sartorius AG
  • 6.3.5 Thermo Fisher Scientific Inc.
  • 6.3.6 Merck KGaA (MilliporeSigma)
  • 6.3.7 Tosoh Bioscience LLC
  • 6.3.8 Waters Corporation
  • 6.3.9 Agilent Technologies Inc.
  • 6.3.10 Shimadzu Corporation
  • 6.3.11 YMC Co. Ltd.
  • 6.3.12 Sepax Technologies Inc.
  • 6.3.13 Repligen Corporation
  • 6.3.14 KNAUER Wissenschaftliche Gerate GmbH
  • 6.3.15 JNC Corporation
  • 6.3.16 Bio-Works Technologies AB
  • 6.3.17 Pall Corporation
  • 6.3.18 Phenomenex Inc.
  • 6.3.19 ChromaTan Corporation
  • 6.3.20 Daicel Chiral Technologies

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment